Evidence map›Paper›PMID 38880375›Full record

ArticleAmerican journal of ophthalmology2024

Incidence and Remission of Post-Surgical Cystoid Macular Edema Following Cataract Surgery in Eyes With Intraocular Inflammation.

Sapna Gangaputra, Craig Newcomb, Gui-Shuang Ying, Sylvia Groth, Tonetta D Fitzgerald, Pichaporn Artornsombudh, Srishti Kothari, Siddharth S Pujari, Douglas A Jabs, Grace A Levy-Clarke and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of ophthalmology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Sapna GangaputraFrom the Vanderbilt Eye Institute (S.G., S.G.), Vanderbilt University Medical Center, Nashville, Tennessee, USA. Electronic address: sapna.gangaputra@vumc.org.
Craig NewcombCenter for Clinical Epidemiology and Biostatistics (C.N.), Department of Biostatistics and Epidemiology, The Perelman School of Medicine, The University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Gui-Shuang YingDepartment of Ophthalmology (G.-S.Y., T.D.F., S.K., N.P.B., K.A.D.), The Perelman School of Medicine, The University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Sylvia GrothFrom the Vanderbilt Eye Institute (S.G., S.G.), Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Tonetta D FitzgeraldDepartment of Ophthalmology (G.-S.Y., T.D.F., S.K., N.P.B., K.A.D.), The Perelman School of Medicine, The University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Pichaporn ArtornsombudhDepartment of Ophthalmology (P.A.), Somdech Phra Pinkloa Hospital, Royal Thai Navy, Bangkok, Thailand; Department of Ophthalmology (P.A.), Chulalongkorn University, Bangkok, Thailand.
Srishti KothariDepartment of Ophthalmology (G.-S.Y., T.D.F., S.K., N.P.B., K.A.D.), The Perelman School of Medicine, The University of Pennsylvania, Philadelphia, Pennsylvania, USA; Massachusetts Eye Research and Surgery Institution (S.K., C.S.F.), Waltham, Massachusetts, USA.
Siddharth S PujariSiddharth Netralaya Superspecialty Eye Hospital (S.S.P.), Belgaum, Karnataka, India.
Douglas A JabsWilmer Eye Institute (D.A.J., J.E.T.), The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Center for Clinical Trials and Evidence Synthesis (D.A.J., J.E.T.), Department of Epidemiology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Grace A Levy-ClarkeDepartment of Ophthalmology and Visual Sciences (G.A.L.-C.), West Virginia University, Morgantown, West Virginia, USA.
Robert B NussenblattLaboratory of Immunology (R.B.N.), National Eye Institute, National Institutes of Health, Bethesda, Maryland, USA.
James T RosenbaumDepartment of Ophthalmology (J.T.R., E.B.S.), Oregon Health and Science University, Portland, Oregon, USA; Department of Medicine (J.T.R.), Oregon Health and Science University, Portland, Oregon, USA; Legacy Devers Eye Institute (J.T.R.), Portland, Oregon, USA.
H Nida SenDepartment of Ophthalmology (H.N.S.), George Washington University, Washington, DC, USA; Janssen Retina Global Clinical Development (H.N.S.), Princeton, New Jersey, USA.
Eric B SuhlerDepartment of Ophthalmology (J.T.R., E.B.S.), Oregon Health and Science University, Portland, Oregon, USA; Portland Veteran's Affairs Medical Center (E.B.S.), Portland, Oregon, USA.
Jennifer E ThorneWilmer Eye Institute (D.A.J., J.E.T.), The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Center for Clinical Trials and Evidence Synthesis (D.A.J., J.E.T.), Department of Epidemiology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Nirali P BhattDepartment of Ophthalmology (G.-S.Y., T.D.F., S.K., N.P.B., K.A.D.), The Perelman School of Medicine, The University of Pennsylvania, Philadelphia, Pennsylvania, USA.
C Stephen FosterMassachusetts Eye Research and Surgery Institution (S.K., C.S.F.), Waltham, Massachusetts, USA; Department of Ophthalmology and Schepens Eye Research Institute (C.S.F., J.H.K.), Massachusetts Eye and Ear Infirmary; and Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, USA.
Kurt A DregerDepartment of Ophthalmology (G.-S.Y., T.D.F., S.K., N.P.B., K.A.D.), The Perelman School of Medicine, The University of Pennsylvania, Philadelphia, Pennsylvania, USA; Department of Population, Family, and Reproductive Health (K.A.D.), Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Jeanine M BuchanichCenter for Occupational Biostatistics and Epidemiology (J.M.B.), University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
John H KempenDepartment of Ophthalmology and Schepens Eye Research Institute (C.S.F., J.H.K.), Massachusetts Eye and Ear Infirmary; and Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, USA; Sight for Souls (J.H.K.), Bellevue, Washington, USA; MCM Eye Unit (J.H.K.), MyungSung Christian Medical Center (MCM) General Hospital and Myung Sung Medical School, Addis Ababa, Ethiopia; Department of Ophthalmology (J.H.K.), Addis Ababa University School of Medicine, Addis Ababa, Ethiopia. Electronic address: John_kempen@meei.harvard.edu.
Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study Research Group

Funding

Long-term Follow-up of the Systemic Immunosuppressive Therapy for Eye Diseases CohortR01EY014943 · NEI · UNIVERSITY OF PENNSYLVANIA · PI KEMPEN, JOHN H · 2004 to 2025
$8.1M
Outcomes of uveitic cataract and uveitic glaucoma surgeryR21EY032592 · NEI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI GANGAPUTRA, SAPNA S · 2021 to 2022
$488k
NEI NIH HHS R01 EY014943NEI NIH HHS R21 EY032592
6 · The paper itself

Abstract

purposeTo evaluate the incidence, remission, and relapse of post-surgical cystoid macular edema (PCME) following cataract surgery in inflammatory eye disease.

methodsA total of 1859 eyes that had no visually significant macular edema prior to cataract surgery while under tertiary uveitis management were included. Standardized retrospective chart review was used to gather clinical data. Univariable and multivariable logistic regression models with adjustment for inter-eye correlations were performed.

resultsPCME causing VA 20/50 or worse was reported in 286 eyes (15%) within 6 months of surgery. Adults age 18-64 years as compared to children (adjusted odds ratio [aOR] = 2.42, for ages 18 to 44 years and aOR = 1.93 for ages 45 to 64 years, overall P = .02); concurrent use of systemic immunosuppression (conventional aOR 1.53 and biologics aOR = 2.68, overall P = .0095); preoperative VA 20/50 or worse (overall P < .0001); cataract surgery performed before 2000 (overall P = .03) and PMCE in fellow eye (aOR = 3.04, P = .0004) were associated with development of PCME within 6 months of cataract surgery. PCME resolution was seen in 81% of eyes at 12 months and 91% of eyes at 24 months. CME relapse was seen in 12% eyes at 12 months and 19% eyes at 24 months.

conclusionsPCME occurs frequently in uveitic eyes undergoing cataract surgery; however, most resolve within a year. CME recurrences likely are due to the underlying disease process and not relapses of PCME.

Indexed as

Macular EdemaPostoperative ComplicationsVisual AcuityAdolescentAdultAgedCataract ExtractionChildFemaleHumansIncidenceLens Implantation, IntraocularMaleMiddle AgedPhacoemulsificationRecurrence

Identifiers

PMID38880375
PMCPMC11486591

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.